IMDCY.US IMDCY
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is IMDCY.US undervalued?
Graham numberThe Graham number of IMDCY cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IMDCY fundamental analysis
No fundamental analysis for IMDCY yet.
IMDCY stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IMDCY
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The comp…
Full company profileFinancial statements of IMDCY are not available yet.
IMDCY dividends
IMDCY has not paid dividends in the last 1 fiscal years.
Who owns IMDCY
Ownership data of IMDCY is not available yet.
IMDCY company profile
- Company name
- IMDCY
- Ticker
- IMDCY.US
- Exchange
- USA Stocks
- Sector
- -
- Industry
- -
- Employees
- 333
- Fiscal year end
- December
- Address
- Building 8W, Phase 2, Hong Kong, Hong Kong
- Website
- insilico.com
About IMDCY
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. InSilico Medicine Cayman TopCo has a strategic collaboration agreement with Takeda to use its proprietary Pharma.AI, to advance drug candidates; and collaboration with Servier for researching and developing programs for oncology. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
IMDCY management
7- Dr. Aleksandrs Zhavoronkov Ph.D.Founder, CEO, Chief Business Officer, Longevity Board Member & Chairman of the Board · born 1980
- Dr. Feng Ren Ph.D.CO-CEO, Chief Scientific Officer, Longevity Board Member & Executive Director · born 1975
- Mr. Peng DaiVP & Head of Finance · born 1985
- Mr. Aleksandr Aliper Ph.D.President · born 1990
- Dr. Xiao DingHead of Chemistry
- Dr. Man ZhangHead of Biology
- Ms. Kwan Wai LeungCompany Secretary · born 1983